The Korean Journal of Medicine

  • 제85권2호
  • /
  • Pages.214-217
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Alemtuzumab을 이용한 이차성 순적혈구 빈혈의 치료

Successful Erythropoietin Therapy after Alemtuzumab and Cyclosporin a Treatment for Epoetin-Induced Pure Red Cell Aplasia

  • 박혜민 (울산대학교 의과대학 울산대학교병원 혈액내과) ;
  • 임재욱 (울산대학교 의과대학 울산대학교병원 혈액내과) ;
  • 박주환 (울산대학교 의과대학 울산대학교병원 혈액내과) ;
  • 김은혜 (울산대학교 의과대학 울산대학교병원 혈액내과) ;
  • 전홍길 (울산대학교 의과대학 울산대학교병원 혈액내과) ;
  • 박재후 (울산대학교 의과대학 울산대학교병원 혈액내과) ;
  • 김혁 (울산대학교 의과대학 울산대학교병원 혈액내과)
  • Park, Hyemin (Division of Hematology and Hematological Malignancies, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Im, Jaeuk (Division of Hematology and Hematological Malignancies, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Park, Juhwan (Division of Hematology and Hematological Malignancies, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Kim, Enhye (Division of Hematology and Hematological Malignancies, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Jun, Honggil (Division of Hematology and Hematological Malignancies, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Park, Jae-Hoo (Division of Hematology and Hematological Malignancies, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Kim, Hawk (Division of Hematology and Hematological Malignancies, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine)
  • 투고 : 2012.11.13
  • 심사 : 2013.02.12
  • 발행 : 2013.08.01
⟨ 이전 논문 다음 논문 ⟩

초록

Pure red cell aplasia (PRCA) in adults is usually idiopathic, although some underlying conditions can cause PRCA. Immunosuppressive therapy (IST) is used to treat PRCA, but IST has side effects and may fail. The anti-CD52 monoclonal antibody alemtuzumab (ALM) was recently used to successfully treat therapy-resistant PRCA. We herein report successful treatment of secondary PRCA after erythropoietin therapy using ALM and cyclosporin A (CsA) in one patient. The total dose of ALM was 60 mg over 3 days (10, 20, and 30 mg, respectively) plus CsA for at least 6 months. The patient achieved a complete response 18 months after ALM-CsA treatment and his treatment could be changed to a different erythropoietin-stimulating agent.

키워드

참고문헌

  1. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 2008;142:505-514. https://doi.org/10.1111/j.1365-2141.2008.07216.x
  2. Kim H, Min YJ, Baek JH, et al. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 2009;33:222-231. https://doi.org/10.1016/j.leukres.2008.08.004
  3. Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148:791-796. https://doi.org/10.1111/j.1365-2141.2009.08027.x
  4. Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 2004;73:389-396. https://doi.org/10.1111/j.1600-0609.2004.00348.x
  5. Sloand EM, Scheinberg P, Maciejewski J, Young NS. Brief communication: successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). Ann Intern Med 2006;144:181-185. https://doi.org/10.7326/0003-4819-144-3-200602070-00006
  6. Bates D. Alemtuzumab. Int MS J 2009;16:75-76.
  7. Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003;123:278-281. https://doi.org/10.1046/j.1365-2141.2003.04609.x
  8. Au WY, Lam CC, Chim CS, Pang AW, Kwong YL. Alemtuzumab induced complete remission of therapyresistant pure red cell aplasia. Leuk Res 2005;29:1213-1215. https://doi.org/10.1016/j.leukres.2005.02.018
  9. Macdougall IC, Roche A, Rossert J, Casadevall N, Francois P, Kemeny DM. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? Nephrol Dial Transplant 2004;19:2901-2905. https://doi.org/10.1093/ndt/gfh368
  10. Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant 2005;20(Suppl 4):iv23-26. https://doi.org/10.1093/ndt/gfh1090